Phase II study of FOLFIRINOX for chemotherapy‐naïve Japanese patients with metastatic pancreatic cancer-Reference-Cited by-同舟云学术

Phase II study of FOLFIRINOX for chemotherapy‐naïve Japanese patients with metastatic pancreatic cancer

Published:2014-09-29 Issue:10 Volume:105 Page:1321-1326
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Okusaka Takuji¹,Ikeda Masafumi²,Fukutomi Akira³,Ioka Tatsuya⁴,Furuse Junji⁵,Ohkawa Shinichi⁶,Isayama Hiroyuki⁷,Boku Narikazu⁸

Affiliation:

1. Department of Hepatobiliary and Pancreatic Oncology National Cancer Center Hospital TokyoJapan

2. Department of Hepatobiliary and Pancreatic Oncology National Cancer Center Hospital East KashiwaJapan

3. Department of Gastrointestinal Oncology Sunto‐gun Cancer Center ShizuokaJapan

4. Department of Hepatobiliary and Pancreatic Oncology Osaka Medical Center for Cancer and Cardiovascular Diseases OsakaJapan

5. Department of Medical Oncology Kyorin University School of Medicine MitakaJapan

6. Department of Hepatobiliary and Pancreatic Oncology Kanagawa Cancer Center YokohamaJapan

7. Department of Gastroenterology Graduate School of Medicine The University of Tokyo TokyoJapan

8. Department of Clinical Oncology St. Marianna University School of Medicine Kawasaki Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.12501

Reference17 articles.

1. Global cancer statistics

2. Japanese Ministry of Health Labour and Welfare.Statistical investigation result.2012: [cited 27 November 2013] Available from URL:http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakutei12/index.html[In Japanese]

3. Center for Cancer control and Information Services Latest Cancer Statistics. [cited 21 November 2013] Available from URL:http://ganjoho.jp/public/statistics/pub/statistics01.html[In Japanese]

4. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

5. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Cited by 146 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase 2 study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer;BJC Reports;2024-01-23

2. Phase II study of SOXIRI (S-1/oxaliplatin/irinotecan) chemotherapy in patients with unresectable pancreatic ductal adenocarcinoma;Pancreatology;2023-12

3. Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation;Biomedical Journal;2023-12

4. Safety and Efficacy Analysis of PD-1 Inhibitors in Combination with Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer: A Real-World, Single-Center Study;OncoTargets and Therapy;2023-11

5. Real‑world treatment outcomes among patients with metastatic pancreatic cancer in Japan: The Tokushukai real‑world data project;Molecular and Clinical Oncology;2023-10-25